Abstract
Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.
| Original language | English |
|---|---|
| Pages (from-to) | 6-7 |
| Number of pages | 2 |
| Journal | Asian Journal of Pharmaceutical and Clinical Research |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 01-04-2017 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmaceutical Science
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Sorafenib induced acneiform eruptions: A case report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver